Altmetrics
Downloads
142
Views
63
Comments
0
A peer-reviewed article of this preprint also exists.
supplementary.pdf (32.42KB )
This version is not peer-reviewed
Submitted:
25 May 2024
Posted:
27 May 2024
You are already at the latest version
Compounds | Disease | Model | Effects and mechanisms | References | ||
---|---|---|---|---|---|---|
in vitro | in vivo | in vitro | in vivo | |||
RES | Autism-spectrumdisorder | KGN cells | Mice: VPA | Improvement of mitochondrial quantity through stimulating SIRT1/PGC-1α | Prevents mPFC neuronal changes, antioxidant and neuroprotective effects; improves E/I balance-related parameters | [55,66] |
C2C12 cells | Mice: BTBR | Neuroprotection through inducing AMPK activation, regulating SIRT-1 protein activity, and promoting mitochondrial biogenesis | Restoration of social interaction and enhancement of socialization in mice, improvement of neuroimmune disorders; suppression of molecules that promote inflammation and the signaling pathway involving TLR/NF-κB transcription factors | [56,67] | ||
BAI | BV-2 cells | Wistar rats: VPA | Improvement of neurocognitive deficits through reversing neuroinflammation, inhibition of HMGB1 release via the SIRT1/HMGB1 pathway, and reducing LPS-induced nuclear translocation of HMGB1 | Enhances postnatal growth and maturity, while also improving motor development, repetitive behaviors, and social impairments in rats who exposed to VPA during prenatal stages. Improved functionality of mitochondria in neurons; increased sirtuin-1 (SIRT1) levels in brain tissue of VPA rats. | [59,68] | |
AFE | RAW 264.7 cells | SD rats: VPA | Suppression of inflammation; blocking of LPS-induced NF-κB and MAPK signaling pathways in RAW264.7 macrophages | Notable enhancements in neurobehavioral alterations seen in the raised plus-T maze, water maze, and rotating rod test; Increases the expression of Nrf2 and HO-1, SIRT-1, and LC3; Decreases the expression of NFκB. | [63,69] | |
HES | BV-2 cells | SD rats: sodium fluoride | Antioxidant, anti-inflammatory, and anti-apoptosis; Inhibition of the TLR4 /p-NF-κB signaling pathway | Ameliorates neurobehavioral disorders and protects the nervous system; modulates Nrf2/Tlr4/NFκB signaling | [65,71] | |
Phlorotannins (PS) | Sleep disorder | HaCaT cells | Mice: Caffeine | ROS inhibition, anti-oxidative stress; Inhibition of the MAPK signaling pathway | Relief of transient insomnia symptoms; Promoting sleep by regulating GABA | [88,95] |
TP | PC12 cells | Mice: inversion light/dark cycle | Anti-oxidative stress; increases p-ATM and p-Chk2 expression, activates DNA repair signaling pathway | Enhancement of internal and peripheral circadian rhythm abnormalities and cognitive impairment;Enhances the quantity of hypothalamic cell clusters, increases the expression of astrocytes and fibroblasts, and ameliorates structural abnormalities in the intestinal microbiota | [90,96] | |
RA | PC12 cells | SD rats: Pentobarbital | Antioxidant stress; mediates Akt/GSK-3β/Fyn pathway activation of Nrf2 | Decreased sleep/wake cycle and REM sleep counts, increased sleep duration; increased glutamic acid decarboxylase and GABAA receptor expression | [94,98] | |
TRE | Anxiety disorder | HaCaT cells | SD rats: TDS | Reduces cytotoxicity and reduces apoptosis, protects against oxidative stress | The TDS-induced decreases in the proportion of time spent in the middle of the arena, open-arm entrance, and time spent in the arena with open arms in the open field and raised cross maze tests were reversed. Reverses the index of adrenal activity and levels of corticotropin-releasing factor (CRF), while enhancing the phosphorylation of cyclic AMP response element-binding protein (pCREB) and levels of brain-derived neurotrophic factor (BDNF). | [116,117] |
CGA | HepG2 cells | Mice: SCOP | Antioxidant stress; Activation of Nrf2, ARE gene and GCL, HO-1 and Sestrin2 expression | Enhances short-term or working memory impairments in the scopolamine-induced Y-maze test, effectively counteracts cognitive impairments in the passive avoidance test in mice, and decreases the time taken to escape in the Morris water maze test; enhances GABA activity, and avoids neurological harm | [110,118] | |
HpE | HepG2 cells | Wistar rats: FG-7142 | Cryoprotection; Activation of Nrf2 and increases GSH levels | Improves anxiety behavior, modulates oxidative stress and inflammatory response; reduces IL-1α, IL-1β, MCP1, IFN, and MIP; reduces MDA levels, increases CAT and SOD activity; reduces CORT levels. | [112,119] | |
GSE | L-02 cells | SD rats: Cd | Counteracts AS-induced oxidative damage and promotes AS methylation metabolism; Activates the Nrf2 signaling pathway | Increases glutathione reductase (GR) levels, restores GST and GPx expression, and decreases MDA levels to prevent oxidative damage, Restores 5-HTT expression | [113,120] | |
CUR | SH-SY5Y cells | Wistar rats: immobilization stress | Inhibition of cellular inflammatory damage; Increased PPARγ protein expression, Increased activity of ROS scavenging enzymes SOD and CAT |
Improves anxiety behavior, prevents stress-induced behavioral deficits, improves memory; Reduces brain MDA levels, elevated CAT, GPx, SOD, and AChE activities. | [114,121] | |
ANT | Depression | BV2 microglial cells | Mice: CUMS | Anti-inflammatory effect; Blocking activation of NF-κB, PI3K/Akt, and MAPK signaling cascade responses in microglia | Depression-like behavior was significantly improved after CUMS treatment; mediation of the ERK/CREB/BDNF signaling pathway was enhanced, which upregulated BDNF and promoted neuronal dendrite development. | [127,131] |
QUE | SH-SY5Y cells | Mice: CUS | Modulation of the NF-κB/HO pathway to inhibit NO and iNOS expression, Prevents NF-κB nuclear translocation and HO-1 downregulation | Markedly decreased anxiety, relieved sadness, improved cognitive impairment, and restored normal motor functioning. Decreased concentrations of indicators of oxidative stress. The levels of TBARS, NO, and antioxidants (total thiols, catalase) were increased. Decreased production of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β, and COX-2) in the hippocampus and injured hippocampal neurons | [130,134] | |
FA | PC12 cells | SD rats: PD | Resistance to oxidative stress in PC12 cells; Inhibits phosphorylation of ERK to attenuate H2O2-induced cellular damage. Increases BDNF by regulating microRNA-10b expression | Amelioration of depressive-like behavior in rats descended from prenatal stress; inhibition of IL-6, IL-1β, and TNF-α, increase in IL-10 mRNA and protein expression, and significant reduction in adrenocorticotropic hormone (ATH) and adrenocorticotropic hormone (ATH) concentrations | [128,134] | |
HMF | C6 cells | Mice: CUMS | Neuroprotective effect; Induction of m-BDNF expression to exert its neuroprotective effect/CREB signaling Inhibits PDE4B or PDE4D |
Amelioration of corticosterone-induced weight loss and depressive-like behavior; up-regulation of BDNF in the hippocampus via the ERK1/2/MAP system | [129,135] |
Compounds | Disease | Type of study | Sample size | Treatment schedule | Finding | Reference |
---|---|---|---|---|---|---|
RES | Autism-spectrum disorder | Randomized double-blind controlled trials | 62 | 250 mg RES twice daily for 10 weeks | No significant impact on irritation, improved ASD hyperactivity/noncompliance | [74] |
Randomized trial ex vivo study | 10 | RES 2 mg kg-1 per day, up to 50 mg per day; 12 weeks total treatment | Resveratrol substantially boosted mtFAO activity, particularly in fibroblasts from individuals with severe symptoms | [76] | ||
Luteolin | Case series of study | 37 | A total of 200 mg of lutein once daily for at least 4 months | Improved speech recovery by 10%, social interaction by 25%, eye contact and attention by 50%, and gastrointestinal and allergy problems in 75% of subjects without side effects | [77] | |
Prospective open label trial |
50 | 200 mg Luteolin per 10 kg body weight for 26 weeks | Significantly enhanced children’s adaptive functioning and conduct, transient (1–8 weeks) irritation, no serious adverse effects | [78] | ||
Case report | 1 | Co-ultraPEA-LUT® at a dose of 700 mg+70 mg | Improved clinical picture and stereotype reduction in a 10-year-old boy | [79] | ||
QUE | Not mentioned | 17 | Supplementation with 250 mg of quercetin per day for 16 months | Some autistic individuals improved their global progress score, social interaction, receptive language, and expressive language | [80] | |
PS | Sleep disorder | Randomized double-blind placebo-controlled trial | 24 | 500 mg/day for 1 week | PS significantly increased “sleep duration” ratings and decreased dyspnea during supine REM sleep without major side effects | [99] |
TP | Double-blind crossover design | 20 | Tea consumption (≥300 ml/day) within 7 days | Reduces stress; improves sleep quality | [100] | |
Randomized, placebo-controlled, double-blind crossover trial | 12 | Oolong tea (100 mg caffeine, 21.4 mg gallic acid, 97 mg catechins, 125 mg polymerized polyphenols) was eaten for 14 days | Increased fat oxidation but no improvement in sleep | [101] | ||
RA | Randomized controlled parallel trials. | 89 | 65 mg daily for 30 days | EGCG and RA enhanced sleep and decreased insomnia | [102] | |
CUR | Anxiety disorder | Parallel double-blind randomized controlled trials | 77 | 500 mg CUR extract for 8 weeks | Notable enhancement in the Gastrointestinal Symptom Rating Scale (GSRS) and the Depression, Anxiety and Stress Scale-21 (DASS-21) | [124] |
AS | Randomized double-blind placebo-controlled trial | 132 | 430 mg, 860 mg and 1290 mg over 29 days | Long-term supplementation may benefit cognitive function and modulate physiological responses to stressors, Significant reduction in observed anxiety symptoms using the STAI score | [125] | |
GSE | Randomized double-blind, placebo-controlled trials | 78 | 300 mg/day for 16 weeks | GSE relieved perceived stress | [126] | |
ANT | Depression | not mentioned | 93 | Different anthocyanin intake | Dietary Deficiencies in ANT may cause major depression | [136] |
AG | Randomized triple-blind placebo-controlled crossover trial | 50 | 1.34 g/day for 4 weeks | Improves BAI and BDI and reduces depression symptoms such as sorrow, weeping, trance, sleeplessness, irritability, exhaustion, loss of libido, and thoughts of punishment | [137] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated